

Filippo Ansaldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592760/publications.pdf>

Version: 2024-02-01

63
papers

2,072
citations

236925

25
h-index

254184

43
g-index

64
all docs

64
docs citations

64
times ranked

3528
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 417-428.	3.4	10
2	Economic burden of pneumococcal disease in children in Liguria, Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	3
3	A comparative analysis of the first and second COVID-19 wave in Italy: evaluation of mortality in the Infectious Disease Unit of Genoa University Hospital.. <i>New Microbiologica</i> , 2021, 44, 245-247.	0.1	0
4	Analysis of a 3-months measles outbreak in western Liguria, Italy: Are hospital safe and healthcare workers reliable?. <i>Journal of Infection and Public Health</i> , 2020, 13, 619-624.	4.1	11
5	Italian Health Care Workersâ€™ Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Infection and Prevention. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5278.	2.6	19
6	Burden and Prevention of HPV. Knowledge, Practices and Attitude Assessment Among Pre-Adolescents and their Parents in Italy. <i>Current Pharmaceutical Design</i> , 2020, 26, 326-342.	1.9	16
7	COVID-19: Some clinical questions after the first 4 months. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13326.	3.4	4
8	The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients â‰¥50 Years. <i>Vaccines</i> , 2020, 8, 20.	4.4	8
9	Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. <i>Pathogens</i> , 2020, 9, 76.	2.8	14
10	Immunization Campaigns and Strategies against Human Papillomavirus in Italy: The Results of a Survey to Regional and Local Health Units Representatives. <i>BioMed Research International</i> , 2019, 2019, 1-8.	1.9	21
11	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	5.8	123
12	Universal influenza virus vaccines: what needs to happen next?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 671-683.	3.1	17
13	Predictors of Mortality with <i>Staphylococcus aureus</i> Bacteremia in Elderly Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1284-1289.	2.6	18
14	Trends of influenza B during the 2010-2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 523-531.	3.3	19
15	Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 456-463.	3.3	21
16	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , 2017, 43, 509-518.	8.2	51
17	Invasive <i>Candida</i> Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. <i>Transplantation Direct</i> , 2017, 3, e156.	1.6	34
18	The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. <i>Vaccine</i> , 2017, 35, 5776-5785.	3.8	56

#	ARTICLE	IF	CITATIONS
19	Volatile Organic Compounds in Anatomical Pathology Wards: Comparative and Qualitative Assessment of Indoor Airborne Pollution. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 609.	2.6	10
20	Global reaction to the recent outbreaks of Zika virus: Insights from a Big Data analysis. <i>PLoS ONE</i> , 2017, 12, e0185263.	2.5	51
21	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. <i>PLoS ONE</i> , 2017, 12, e0170236.	2.5	67
22	Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. <i>PLoS ONE</i> , 2017, 12, e0177985.	2.5	69
23	State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. <i>Journal of Immunology Research</i> , 2016, 2016, 1-19.	2.2	26
24	The Molecular Epidemiology and Evolutionary Dynamics of Influenza B Virus in Two Italian Regions during 2010–2015: The Experience of Sicily and Liguria. <i>International Journal of Molecular Sciences</i> , 2016, 17, 549.	4.1	21
25	Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1140.	4.1	19
26	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASC), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	3.3	49
27	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. <i>Critical Care</i> , 2016, 20, 246.	5.8	9
28	Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review. <i>Advances in Therapy</i> , 2016, 33, 1094-1104.	2.9	22
29	Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2616-2627.	3.3	37
30	Alcohol and liver transplantation: the 6-month abstinence rule is not a dogma. <i>Transplant International</i> , 2016, 29, 953-954.	1.6	8
31	Vaccine-preventable infections in Systemic Lupus Erythematosus. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 632-643.	3.3	26
32	Clinical and Therapeutic Aspects of Candidemia: A Five Year Single Centre Study. <i>PLoS ONE</i> , 2015, 10, e0127534.	2.5	90
33	Latent Tuberculosis Infection among a Large Cohort of Medical Students at a Teaching Hospital in Italy. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	17
34	Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience. <i>Intensive Care Medicine</i> , 2015, 41, 2026-2028.	8.2	6
35	Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 166-171.	3.3	9
36	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 9633.	3.3	135

#	ARTICLE	IF	CITATIONS
37	Molecular and Serological Diversity of <i>Neisseria meningitidis</i> Carrier Strains Isolated from Italian Students Aged 14 to 22 Years. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1901-1910.	3.9	40
38	Carriage of <i>Streptococcus pneumoniae</i> in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 614-620.	3.3	25
39	Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 591-598.	3.3	25
40	Carriage of <i>Streptococcus pneumoniae</i> 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy. <i>Vaccine</i> , 2012, 30, 2288-2294.	3.8	17
41	Intanza® 15mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. <i>Vaccine</i> , 2012, 30, 2908-2913.	3.8	27
42	Fluzone® Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. <i>Expert Review of Vaccines</i> , 2012, 11, 17-25.	4.4	33
43	The Authors' Reply. <i>Drugs and Aging</i> , 2011, 28, 505-507.	2.7	0
44	Epidemiological changes after PCV7 implementation in Italy: Perspective for new vaccines. <i>Hum Vaccin</i> , 2011, 7, 211-216.	2.4	19
45	Increasing Incidence of <i>Streptococcus pneumoniae</i> Serotype 19A and Emergence of Two Vaccine Escape Recombinant ST695 Strains in Liguria, Italy, 7 Years after Implementation of the 7-Valent Conjugated Vaccine. <i>Vaccine Journal</i> , 2011, 18, 343-345.	3.1	25
46	Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 415-427.	3.1	40
47	Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. <i>Vaccine</i> , 2010, 28, 4123-4129.	3.8	87
48	Syndrome surveillance and molecular epidemiology for early detection and tracing of an outbreak of measles in Liguria, Italy. <i>Journal of Medical Virology</i> , 2009, 81, 1807-1813.	5.0	13
49	Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection. <i>Vaccine</i> , 2009, 27, 3345-3348.	3.8	25
50	Simultaneous Detection of Anti-HCV Antibody and HCV Core Antigen. <i>Methods in Molecular Biology</i> , 2009, 510, 15-23.	0.9	3
51	Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. <i>European Journal of Epidemiology</i> , 2008, 23, 45-53.	5.7	23
52	Cross-protection by MF59®, adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. <i>Vaccine</i> , 2008, 26, 1525-1529.	3.8	117
53	Burden of Rotavirus-Associated and Non-Rotavirus-Associated Diarrhea among Nonhospitalized Individuals in Central Italy: A 1-Year Sentinel-Based Epidemiological and Virological Surveillance. <i>Clinical Infectious Diseases</i> , 2008, 46, e51-e55.	5.8	10
54	Molecular Characterization of a New Variant of Rotavirus P[8]G9 Predominant in a Sentinel-Based Survey in Central Italy. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1011-1015.	3.9	19

#	ARTICLE	IF	CITATIONS
55	Neutralizing and Hemagglutination-Inhibiting Activities of Antibodies Elicited by the 2004-2005 Influenza Vaccine against Drifted Viruses. <i>Vaccine Journal</i> , 2006, 13, 162-164.	3.1	12
56	Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. <i>Journal of Medical Virology</i> , 2005, 76, 327-332.	5.0	153
57	New A/H3N2 Influenza Variant: a Small Genetic Evolution but a Heavy Burden on the Italian Population during the 2004-2005 Season. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3027-3029.	3.9	24
58	Antigenic characterisation of influenza B virus with A new microneutralisation assay: Comparison to haemagglutination and sequence analysis. <i>Journal of Medical Virology</i> , 2004, 74, 141-146.	5.0	16
59	Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons. <i>Journal of Medical Virology</i> , 2004, 74, 629-640.	5.0	29
60	Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season. <i>Journal of Medical Virology</i> , 2003, 70, 463-469.	5.0	39
61	Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. <i>Journal of Medical Virology</i> , 2001, 64, 199-206.	5.0	4
62	Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. <i>Journal of Medical Virology</i> , 2001, 63, 17-21.	5.0	43
63	Novel Approach To Reduce the Hepatitis C Virus (HCV) Window Period: Clinical Evaluation of a New Enzyme-Linked Immunosorbent Assay for HCV Core Antigen. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3110-3114.	3.9	86